Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › rituximab

rituximab

40 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of rituximab

424 trials tracked of rituximab: 83 in phase 3 or 4 and 34 with published results. The most-cited published study has 988 citations.

424Trials tracked
83Phase 3 & 4
0Recruiting
34With published results
Phase distribution
Phase 4 8 Phase 3 75 Phase 2 304 Phase 1 12 Other / NA 25
  1. Phase 3 A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis Completed · 988 cited
  2. Phase 3 A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma Completed · 618 cited
  3. Phase 3 MEmbranous Nephropathy Trial Of Rituximab Completed · 603 cited
  4. Phase 3 A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3) Completed · 511 cited
  5. Phase 3 Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma Completed · 427 cited
  6. Phase 3 Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma) Completed · 422 cited
Show 44 more trials
  1. Phase 3 A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Completed · 411 cited
  2. Phase 3 Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma Completed · 364 cited
  3. Phase 3 Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia Completed · 351 cited
  4. Phase 3 SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma Completed · 341 cited
  5. Phase 3 A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Completed · 304 cited
  6. Phase 3 Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma Completed · 270 cited
  7. Phase 3 Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela ) Completed · 247 cited
  8. Phase 3 Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in MALT Lymphoma Completed · 226 cited
  9. Phase 3 A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma Completed · 218 cited
  10. Phase 3 A Study Evaluating the Safety and Efficacy of Rituximab in Patients With Myasthenia Gravis Completed · 200 cited
  11. Phase 3 Comparison of Clinical Effects of Azathioprine and Rituximab NMO-SD Patients Completed · 191 cited
  12. Phase 3 A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a Completed · 151 cited
  13. Phase 3 Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL) Completed · 138 cited
  14. Phase 3 Rituximab Vasculitis Maintenance Study Completed · 119 cited
  15. Phase 3 A Study to Evaluate the Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil (MMF) in Participants With Pemphigus Vulgaris (PV) Completed · 115 cited
  16. Phase 3 A Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE) - BLISS-BELIEVE Completed · 111 cited
  17. Phase 3 GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma (ASSIST_FL) Completed · 82 cited
  18. Phase 3 To Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan Completed · 75 cited
  19. Phase 3 A Study Comparing Maintenance Subcutaneous Rituximab With Observation Only in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to Rituximab-based Immunochemotherapy Induction and 2-year Maintenance With Subcutaneous Rituximab Completed · 65 cited
  20. Phase 3 To Compare Efficacy and Safety Between CT-P10 and Rituxan in Patients With Low Tumour Burden Follicular Lymphoma Completed · 63 cited
  21. Phase 3 PK Similarity Prospective Phase 3 Study in Patients With Rheumatoid Arthritis Completed · 53 cited
  22. Phase 3 A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM) Completed · 32 cited
  23. Phase 3 A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma Completed · 27 cited
  24. Phase 3 Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab Completed · 19 cited
  25. Phase 3 MabRella Study: A Study to Evaluate the Safety of Switching From Intravenous to Subcutaneous Administration of Rituximab During First-Line Treatment for Lymphoma Completed · 16 cited
  26. Phase 3 Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma Completed · 16 cited
  27. Phase 3 A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma Completed · 9 cited
  28. Phase 4 Immune Intervention With Rituximab to Preserve Beta Cell Function in Early Onset Type 1 Diabetes Completed · 6 cited
  29. Phase 4 Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis Completed
  30. Phase 4 Rituximab (RTX) Therapy in Patients With Active TAO Completed
  31. Phase 4 Randomized Trial of Induction Therapies in High Immunological Risk Kidney Transplant Recipients Completed
  32. Phase 4 A Study on The Safety of Administering Rituximab at A More Rapid Rate in Patients With Rheumatoid Arthritis Completed
  33. Phase 4 Desensitization in Kidney Transplantation Completed
  34. Phase 4 An Exploratory Study of the Safety and Efficacy of Prophylactic Immunomodulatory Treatment in Myozyme-naive Cross-Reacting Immunologic Material (CRIM[-]) Patients With Infantile-Onset Pompe Disease Completed
  35. Phase 4 A Study of MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNF Therapies. Completed
  36. Phase 3 Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patients Completed
  37. Phase 3 A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphoma Completed
  38. Phase 3 A Study to Assess the Effect of Maintenance Treatment With Rituximab Versus No Treatment in Participants With Progressive B-Cell Chronic Lymphocytic Leukemia (CLL) Completed
  39. Phase 3 Safety of Switching From Rituximab to Ocrelizumab in MS Patients Completed
  40. Phase 3 A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) Completed
  41. Phase 3 Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients Completed
  42. Phase 3 MabionCD20 Compared to MabThera in Lymphoma Patients Completed
  43. Phase 3 Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A Completed
  44. Phase 3 A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation Completed

Showing the 50 most-cited and recently-updated of 424 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Phase 2 trial compares Inotuzumab Ozogamicin plus R-CVP for DLBCL patients unfit for anthracycline
Hematology Phase II
Phase 2 trial compares Inotuzumab Ozogamicin plus R-CVP for DLBCL patients unfit for anthracycline Can a new drug combination help lymphoma patients who can't take standard chemo?
A Phase 2 interventional trial enrolled 129 patients with diffuse large B-cell lymphoma (DLBCL) who were unsuitable for anthracycline-contai…
A new drug combo aims to treat aggressive lymphoma in older patients who can't take standard chemo due to heart risks.
CT.gov Apr 9, 2026
Case report: Orelabrutinib-rituximab with intravitreal methotrexate shows response in primary vitreoretinal lymphoma
Oncology Sys. Review
Case report: Orelabrutinib-rituximab with intravitreal methotrexate shows response in primary vitreoretinal lymphoma Can a new drug combination help treat a rare eye cancer?
A case report with literature review describes one patient with primary vitreoretinal lymphoma (PVRL) treated with orelabrutinib and rituxim…
A new drug combination improved vision and controlled tumors in a patient with a rare eye cancer, with no reported side effects.
Frontiers Apr 7, 2026
Rituximab with prednisone reduced proteinuria in Sjögren's syndrome-associated membranous nephropathy case
Diabetes & Endocrinology Sys. Review
Rituximab with prednisone reduced proteinuria in Sjögren's syndrome-associated membranous nephropathy case Rituximab treatment reduced kidney protein loss in one Sjögren's syndrome patient
A case report describes a 48-year-old female with primary Sjögren's syndrome and nephrotic-range proteinuria treated with prednisone and rit…
A 48-year-old woman with Sjögren's syndrome saw her kidney protein loss drop from 8.5 to 2.2 grams after receiving rituximab treatment.
Frontiers Apr 3, 2026
Obinutuzumab induced remission in FSGS patient after rituximab failure in case report
Nephrology
Obinutuzumab induced remission in FSGS patient after rituximab failure in case report Obinutuzumab helped one patient with kidney disease after rituximab did not work
A case report describes a 33-year-old woman with primary FSGS and nephrotic syndrome who achieved complete remission after obinutuzumab foll…
When rituximab failed to stop protein leakage in a kidney disease patient, a single dose of obinutuzumab restored remission without side eff…
Frontiers Apr 1, 2026